Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effectiveness and Efficacy of Dynamic Optimal Timing, a Smart Phone App for Avoiding Pregnancy: an Observational Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02833922
Recruitment Status : Completed
First Posted : July 14, 2016
Results First Posted : February 17, 2020
Last Update Posted : February 17, 2020
Sponsor:
Collaborators:
Cycle Technologies
Institute for Reproductive Health, Georgetown University
EastBanc Technologies
Information provided by (Responsible Party):
Victoria Jennings, PhD, Georgetown University

Brief Summary:
The purpose of this study is to assess the effectiveness and efficacy of Dynamic Optimal Timing (DOT), an app-based method of family planning that can be used via Android devices, for women who use the method to avoid pregnancy.

Condition or disease Intervention/treatment
Desire to Avoid Pregnancy Behavioral: Women using Dot to avoid pregnancy

Detailed Description:

This is a prospective, efficacy study of the Dynamic Optimal Timing (Dot), an app-based method of family planning that provides the user with information about her daily probability of pregnancy based on the length of her menstrual cycles over time. To use the app, women enter the first day of their menstrual period. Women are then provided information about their daily risk of pregnancy for that day, which they can then use to avoid having unprotected sex. The study is being conducted by the Institute for Reproductive Health (IRH) at Georgetown University.

The study will examine the relationship between women's use of the Dot method (both perfect and typical use) and their pregnancy outcomes at the end of the study. The study will also look at several additional secondary outcomes, such as perceived partner support for the method, coital frequency during the fertile time, and intention to continue using the method after study discontinuation, as well as several other variables around the acceptability of conducting an efficacy study via an app.

The study will recruit women who have already downloaded the DOT app on their Android phones. The study will only recruit women who have previously set their intent in the Dot app as "avoid pregnancy" and entered their second period start date into the app. Eligible women will be: between 18 and 39 years old, have not been pregnant or used hormonal contraception in the last 3 months, are sexually active in a relationship with a male partner, and desire to avoid pregnancy for at least one year.

Women who are consented and entered into the study will activate a "research module" within the Dot app. This module is essentially an "overlay" to the DOT app. It does not change the app itself in any way, but provides a data platform for researchers to obtain self-reported data from study participants about their daily sexual history and to collect periodic surveys from participants on topics pertaining to the study primary and secondary outcomes. Women who report pregnancy, or who fail to enter a new cycle start date within the 40-day window allowed by the Dot method, will be contacted and sent urine pregnancy tests, to confirm their pregnancy status. Participants will complete a maximum of 13 menstrual cycles (approximately 1 year) in the study.

Layout table for study information
Study Type : Observational
Actual Enrollment : 718 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Perfect- and Typical-use Effectiveness of the Dot Fertility App Over 13 Cycles: Results From a Prospective Contraceptive Effectiveness Trial
Study Start Date : September 2016
Actual Primary Completion Date : September 30, 2019
Actual Study Completion Date : September 30, 2019

Group/Cohort Intervention/treatment
Women using Dot to avoid pregnancy
Women living in the United States, ages 18-39 who have not used hormonal birth control or been pregnant in the last three months, who are in a relationship with a male sexual partner, and who wish to use the Dot app to avoid pregnancy for at least one year.
Behavioral: Women using Dot to avoid pregnancy
Women who have chosen to use Dot to prevent pregnancy will be followed for 13 cycles to assess perfect and typical use of the Dynamic Optimal Timing method.




Primary Outcome Measures :
  1. Pregnancy Rates [ Time Frame: 1 year ]
    Pregnancy rates during perfect and typical use of the Dynamic Optimal Timing method to avoid pregnancy in a way directly comparable to the approach used in recent family planning effectiveness studies


Secondary Outcome Measures :
  1. Intent to Continue Using the Method at Study Completion [ Time Frame: 1 year ]
    46.8% of women reported on their 13th cycle that they intend to keep using Dot to prevent pregnancy.

  2. Perceived Partner Support [ Time Frame: 1 year ]
    687 out of 718 women completed the survey where we asked about perceived partner support. The survey was not mandatory and some women did not complete the study or exited the study prior to its administration.

  3. User Acceptability of App-based, Self-reported Data Collection [ Time Frame: 1 year ]
  4. User Perceived Impact of the Dot App [ Time Frame: 1 year ]
    The Dot app has increased my awareness of the importance of knowing my fertile window, in order to prevent pregnancy



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 39 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
The population of eligible participants for this study is women who 1) have begun using Dot for pregnancy prevention; 2) entered their second period start date (i.e., have completed one cycle - in whole or in part - of Dot use), and 3) have indicated that their first cycle was 20-40 days long.
Criteria

Inclusion Criteria:

  • Have downloaded the Android app and selected to use it for pregnancy prevention and have indicated that they are interested in participating in the study;
  • Have provided contact information to learn more about the study or called the call center;
  • Are between 18 and 39 at the time of admission;
  • Have menstrual cycles between 20-40 days at the time of enrollment
  • Are sexually active with a male partner;
  • Have not been pregnant or using any hormonal method of family planning within the past three months
  • Are willing to install a password or biometric protection on their phone to ensure the confidentiality of their study data; and
  • Live in the U.S.

Exclusion Criteria:

Women who do not meet one or more of the inclusion criteria will be excluded from the study.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02833922


Sponsors and Collaborators
Georgetown University
Cycle Technologies
Institute for Reproductive Health, Georgetown University
EastBanc Technologies
Investigators
Layout table for investigator information
Principal Investigator: Victoria Jennings, PhD Institute for Reproductive Health at Georgetown University
  Study Documents (Full-Text)

Documents provided by Victoria Jennings, PhD, Georgetown University:
Study Protocol  [PDF] January 1, 2017
No Statistical Analysis Plan (SAP) exists for this study.

Publications of Results:
Other Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Victoria Jennings, PhD, Director, Georgetown University
ClinicalTrials.gov Identifier: NCT02833922    
Other Study ID Numbers: GR409775
First Posted: July 14, 2016    Key Record Dates
Results First Posted: February 17, 2020
Last Update Posted: February 17, 2020
Last Verified: February 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No